pI: 8.793 |
Length (AA): 353 |
MW (Da): 38735 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
11 | 55 | 4xa1 (D) | 13 | 1209 | 18.00 | 0 | 0.02 | 0.303279 | -0.12 |
12 | 77 | 2l9l (A) | 4 | 66 | 30.00 | 0 | 0.03 | 0.293769 | 1.3 |
57 | 347 | 4oo1 (H) | 6 | 351 | 34.00 | 0 | 1 | 1.06816 | 0.68 |
82 | 352 | 2nn6 (H) | 25 | 292 | 39.00 | 0 | 1 | 1.09601 | 0.74 |
84 | 159 | 3m7n (A) | 4 | 79 | 43.00 | 0.0000000082 | 0.82 | 0.488997 | 1.51 |
137 | 214 | 1sro (A) | 5 | 74 | 24.00 | 0 | 0.91 | 0.299763 | 0.94 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | ME49 Tachyzoite, ME49 merozoite, ME49 Oocyst. | Gregory Hehl AB Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | VEG Tachyzoite, ME49 Bradyzoite. | Gregory Sibley/Greg |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Gregory | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Sibley/Greg | ToxoDB |
Ortholog group members (OG5_127653)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G03360 | ribosomal RNA processing protein 4 |
Babesia bovis | BBOV_III010600 | conserved hypothetical protein |
Brugia malayi | Bm1_33895 | exosome component 2 |
Candida albicans | CaO19.8884 | similar to S. cerevisiae RRP4 (YHR069C) exosome component involved mRNA degradation and nuclear RNA processing |
Candida albicans | CaO19.1304 | similar to S. cerevisiae RRP4 (YHR069C) exosome component involved mRNA degradation and nuclear RNA processing |
Caenorhabditis elegans | CELE_Y73B6BL.3 | Protein EXOS-2 |
Cryptosporidium hominis | Chro.80348 | hypothetical protein |
Cryptosporidium parvum | cgd8_2980 | hypothetical protein |
Dictyostelium discoideum | DDB_G0291310 | hypothetical protein |
Drosophila melanogaster | Dmel_CG3931 | CG3931 gene product from transcript CG3931-RA |
Echinococcus granulosus | EgrG_000535000 | Exosome complex exonuclease RRP4 |
Entamoeba histolytica | EHI_163510 | exosome complex exonuclease RRP4, putative |
Echinococcus multilocularis | EmuJ_000535000 | Exosome complex exonuclease RRP4 |
Giardia lamblia | GL50803_33022 | Hypothetical protein |
Homo sapiens | ENSG00000130713 | exosome component 2 |
Leishmania braziliensis | LbrM.14.0010 | exosome complex exonuclease, putative,ribosomal RNA processing protein 4, putative |
Leishmania donovani | LdBPK_140010.1 | exosome complex exonuclease, putative |
Leishmania infantum | LinJ.14.0010 | exosome complex exonuclease, putative,ribosomal RNA processing protein 4, putative |
Leishmania major | LmjF.14.0010 | exosome complex exonuclease, putative,ribosomal RNA processing protein 4, putative |
Leishmania mexicana | LmxM.14.0010 | exosome complex exonuclease, putative,ribosomal RNA processing protein 4, putative |
Loa Loa (eye worm) | LOAG_00357 | Rrp4-PA |
Mus musculus | ENSMUSG00000039356 | exosome component 2 |
Neospora caninum | NCLIV_047850 | exosome complex exonuclease, putative |
Oryza sativa | 4336421 | Os04g0520000 |
Plasmodium berghei | PBANKA_1007800 | exosome complex component RRP4, putative |
Plasmodium falciparum | PF3D7_0410400 | exosome complex component RRP4, putative |
Plasmodium knowlesi | PKNH_0308500 | exosome complex component RRP4, putative |
Plasmodium vivax | PVX_000730 | exosome complex component RRP4, putative |
Plasmodium yoelii | PY02309 | hypothetical protein |
Saccharomyces cerevisiae | YHR069C | Rrp4p |
Schistosoma japonicum | Sjp_0218320 | ko:K03679 RNA-binding protein Rrp4 and related proteins, putative |
Schistosoma mansoni | Smp_064260 | rrp4 |
Schmidtea mediterranea | mk4.003371.01 | Exosome complex component RRP4 |
Trypanosoma brucei gambiense | Tbg972.7.5280 | ribosomal RNA processing protein 4,exosome complex exonuclease |
Trypanosoma brucei | Tb927.7.4670 | ribosomal RNA processing protein 4 |
Trypanosoma congolense | TcIL3000_0_13330 | ribosomal RNA processing protein 4 |
Trypanosoma cruzi | TcCLB.510167.29 | exosome complex exonuclease, putative |
Trypanosoma cruzi | TcCLB.508859.109 | ribosomal RNA processing protein 4, putative |
Toxoplasma gondii | TGME49_224860 | exosome component 2, putative |
Theileria parva | TP02_0081 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_246740 | rrp4, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.4670 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.4670 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.4670 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.7.4670 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
YHR069C | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_1007800 | Plasmodium berghei | Essential | plasmo |
TGME49_224860 this record | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.